Date: 2017-03-31
Type of information: Private placement
Company: Osmia Pharmaceuticals (Sweden)
Investors:
Amount: SEK 42 million (€ 4.4 million)
Funding type: private placement
Planned used: Oasmia Pharmaceutical intends to use the proceeds from the private placement to strengthen its working capital as well as finance its continuing operations. This financing will give Oasmia time to finalize certain ongoing activities which the Board of Directors anticipates will be the basis to fulfil the company’s long term commercial strategy. Oasmia Pharmaceutical develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications.
Others: • On March 31, 2017, Oasmia Pharmaceutical announced that the company has completed a private placement of a convertible loan in the amount SEK 42,000,193 and placed with a limited group of investors. The private placement, which was announced on 30 March 2017, has enabled Oasmia to place 42 new convertible instruments with a limited group of investors at a nominal value of SEK 1,000,004.60 per convertible instrument through an accelerated book building procedure. The conversion rate is based on the closing price of Oasmia’s shares on Nasdaq Stockholm on 30 March 2017 and will amount to SEK 5.95. The loan matures on 25 April 2017 if not converted to shares, called for by either the convertible holder or the company, or repaid earlier.
Therapeutic area: Cancer - Oncology - Veterinary medicine
